Momelotinib treatment-emergent neuropathy: Prevalence, risk factors and outcome in 100 patients with myelofibrosis

British Journal of Haematology

Volumn 169, Issue 1, 2015, Pages 77-80

  Abdelrahman, Ramy A ^a   Begna, Kebede H ^a   Al Kali, Aref ^a   Hogan, William J s ^a   Litzow, Mark R ^a   Pardanani, Animesh ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

Momelotinib; Myelofibrosis; Myeloproliferative; Neuropathy

Indexed keywords

HYDROXYUREA; JANUS KINASE 1 INHIBITOR; JANUS KINASE 2 INHIBITOR; LENALIDOMIDE; MOMELOTINIB; POMALIDOMIDE; THALIDOMIDE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; JAK1 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 1; JANUS KINASE 2; N-(CYANOMETHYL)-4-(2-((4-(4-MORPHOLINYL)PHENYL)AMINO)-4-PYRIMIDINYL)BENZAMIDE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; PERIPHERAL NEUROPATHY; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; ENZYMOLOGY; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIMARY MYELOFIBROSIS;

ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; FEMALE; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM DISEASES; PREVALENCE; PRIMARY MYELOFIBROSIS; PYRIMIDINES; RISK FACTORS;

EID: 84924965031     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13262     Document Type: Article

References (6)

1. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W. & Pardanani, A. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392-397.
2. Pardanani, A., Laborde, R.R., Lasho, T.L., Finke, C., Begna, K., Al-Kali, A., Hogan, W.J., Litzow, M.R., Leontovich, A., Kowalski, M. & Tefferi, A. (2013a) Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia, 27, 1322-1327.
3. Pardanani, A., Harrison, C.N., Cortes, J.E., Cervantes, F., Mesa, R.A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A.M., Drummond, M., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Gao, G.Z. & Tefferi, A. (2013b) Results OF a Randomized, Double-Blind, Placebo-Controlled Phase III Study (JAKARTA) Of The JAK2-Selective Inhibitor Fedratinib (SAR302503) In Patients With Myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts), 122, 393.
4. Shah, N.P., Olszynski, P., Sokol, L., Verstovsek, S., Hoffman, R., List, A.F., Cortes, J., Kantarjian, H.M., Gilliland, D.G., Clary, D.O., Bui, L.A. & Wadleigh, M. (2008) A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis. Blood (ASH Annual Meeting Abstracts), 112, 98.
5. Tefferi, A., Barosi, G., Mesa, R.A., Cervantes, F., Deeg, H.J., Reilly, J.T., Verstovsek, S., Dupriez, B., Silver, R.T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, L.A. Jr, Camoriano, J.K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J.W., Hoffman, R., Cross, N.C., Gilliland, D.G. & Kantarjian, H. (2006) International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108, 1497-1503.
6. Zhang, Q., Zhang, Y., Diamond, S., Boer, J., Harris, J.J., Li, Y., Rupar, M., Behshad, E., Gardiner, C., Collier, P., Liu, P., Burn, T., Wynn, R., Hollis, G. & Yeleswaram, S. (2014) The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy. Drug Metabolism and Disposition, 42, 1656-1662.